Diversa Corporation (DVSA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diversa Corporation (DVSA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Greg S. who started this subject	1/17/2001 6:14:25 AM
From: nigel bates	of 144

Jan. 17 /PRNewswire/ -- Diversa Corporation (Nasdaq: DVSA - news) today announced the issuance of U.S. Patent No. 6,174,673, covering high- throughput screening of gene libraries made from mixed populations of organisms using fluorescent detection. Fluorescent screening is one of the most sensitive and effective methods available to identify novel bioactive molecules. This patent covers methods utilizing any fluorescent substrate and any fluorescent analyzer, including Charge Coupled Devices (CCD) and FACS (Fluorescence Activated Cell Sorter) instruments, which are capable of screening a billion genes per day. Diversa is using a number of ultra high-throughput screening methods to discover enzymes and small molecules from its extensive, proprietary libraries for use in pharmaceutical, agricultural, chemical processing, and industrial markets. This patent is part of a portfolio of issued patents and patent applications Diversa has filed protecting the screening of libraries of both natural and evolved genes and gene pathways. Diversa's patent estate now consists of 38 issued patents, 7 notices of allowance and over 155 filed patent applications....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next